Coeptis Therapeutics, Inc. (COEP) - חוב לטווח ארוך להון

Coeptis Therapeutics (COEP) is developing universal T-cells to combat blood cancer, thereby increasing patient survival rates. A long debt-to-equity ratio demonstrates financial stability, while the 0.01 metric confirms the current level. Innovations in personalized therapy drive the potential for market capitalization growth. Meanwhile, the company relies on external contractors for drug testing while maintaining strict internal control.

This indicator determines the extent of the company's reliance on long-term borrowings relative to its own equity. Current long-term debt-to-equity dynamics allow for an assessment of financial stability and the risks of cash flow gaps. The calculation is based on the ratio of liabilities with a maturity of more than one year to the amount of shareholders' equity. For Coeptis Therapeutics (COEP), this is critical when financing the environmental modernization of laboratories. Implementing filtration systems and green energy requires long-term capital without compromising liquidity.